

## Karolinska Development EGM 2021: Information on candidates nominated for election to the board

### **Björn Cochlovius**

Born 1968. Ph.D., Assoc.Prof.

Chairman since 2020 (elected Chairman by the board when the, by the annual general meeting 2020, elected Chairman Hans Wigzell resigned).

Other appointments Chairman of Isogencia Ltd, found of and General Manager in BC BioMed Consulting GmbH, Partner in Jürg Kurmann Merger and Acquisitions AG, Associate Professor Immunology at Ruprecht-Karls Universität Heidelberg.

Previous assignments include Senior Director Development Asia-Pacific i Abbvie Inc., member and Head Oncology in Otsuka, co-founder, Interim-CEO and Chariman in Ciliatech AG, Director Business Development Oncology in Roche AG, internal strategy consultat with Alpharma AS (nowadays Axellia), acting CEO of OnTarget Neurology AS, Head R&D at Affitech AS.

Independent of the company and its executive management, and independent in relation to the company's major shareholders.

No holdings in Karolinska Development.

### **Anna Lefevre Skjöldebrand**

Born 1969. Masters of Law.

Other appointments CEO, Swedish Medtech Service AB. Current board assignments include Sweden Medtech4Health AB (chairperson), Dedicare AB, Swecare, COCIR, member of the advisory board Life Science office of Sweden.

Previous assignments include Head of Legal Swedish Medtech Service AB, Lawyer Delphi & Co, Lawyer GLS Legal, Lawyer Ernst & Young Law, Legal Counsel Front Capital Systems AB. Previous board assignments include The e-Health agency, SIS AB and Medtech Europe. She has also been a member of the board in the Board for Public Procurement.

Independent of the company and its executive management, and independent in relation to the company's major shareholders.

No holdings in Karolinska Development.

### **Ben Toogood**

Born 1976, BPharm. MSc. MBA

Other appointments, Head Global Business Development, Sino Biopharmaceuticals Limited.

Previous assignments, Head Global BD & M&A Sandoz AG, Group New Business Development Executive Aspen Pharmacare Holdings, Vice President Global Business

Development Pharmathen SA, International Licensing Executive Niche Generics (Unichem Laboratories), Regulatory Affairs Merck Generics (Mylan).

Independent of the company and its executive management. Not independent in relation to the company's major shareholders.

No holdings in Karolinska Development.